by Elena Iemma | May 28, 2025 | News
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ — EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the...
by Elena Iemma | May 19, 2025 | Blog
FDA Roadmap to Reducing Animal Testing:A Step Toward Smarter Tools for in silico Immunogenicity Risk Assessment The FDA’s new Roadmap to Reducing Animal Testing in Preclinical Safety Studies lays out a phased plan to move away from animal models and toward...
by Elena Iemma | Apr 30, 2025 | Events
The 11th annual Amsterdam Immunogenicity & Tolerance Seminar November 7, 2025 | 8:30 am – 4:00 pm with reception to follow | The Hilton Apollolaan Hotel Registration is now closed About the Amsterdam Immunogenicity & Tolerance Seminar: Now in its 11th...
by Elena Iemma | Apr 30, 2025 | Events
The 17th annual Westin Immunogenicity Seminar Thursday, September 25, 2025 | 9:00 am – 6:00 pm | The Westin Hotel, Meguro, Tokyo Registration is closed Join us for the 17th Annual Westin Immunogenicity Seminar, a free event bringing together leaders in...
by Elena Iemma | Apr 30, 2025 | Blog
Is “Artificial” Intelligence an Option for your ADA? In Case You Missed It: Better ADA Prediction! Guilhem Richard, our CTO, recently presented our new ADA (anti-drug antibody) prediction model to the Antibody Society. The accuracy of the model improved...
